Phenotype Switching in Pediatric Inflammatory Skin Diseases During Biologic Therapy: A Literature Review Focused on Atopic Dermatitis and Psoriasis
- 1Department of Dermatology, Cathay General Hospital, Taipei City 106, Taiwan
- 2Department of Dermatology, Sijhih Cathay General Hospital, New Taipei City 221037, Taiwan
Abstract
Biologic therapies are highly efficacious for pediatric atopic dermatitis (AD) and psoriasis (PsO); however, their expanding use has led to increased reports of phenotype switching—a paradoxical condition where biologics induce new-onset immune-mediated dermatoses. To address clinical uncertainty regarding these complex reactions, this review evaluates real-world case reports, case series, and observational studies of pediatric AD and PsO patients who developed phenotypic switching during biologic therapy. Dupilumab is the most frequently implicated agent, commonly inducing psoriasiform, pustular, or palmoplantar eruptions in AD patients via a compensatory shift from Th2- to Th17-predominant immunity. Conversely, phenotype switching from IL-12/23 and TNF-α inhibitors remains rare in pediatric dermatology. For severe, refractory cases or AD-PsO overlaps, Janus kinase (JAK) inhibitors demonstrate significant rescue efficacy, provided appropriate baseline and ongoing laboratory monitoring is maintained. Pediatric patients experiencing biologic-induced phenotype switching can be successfully managed in clinical practice through early recognition and the implementation of the practical, evidence-based treatment algorithm proposed in this review.
Related
- Margarita Dermatitis Revisited: A Case Report and Literature Review of Lime-Associated Phytophotodermatitis
- Vitiligo developing during dupilumab treatment in a child with atopic dermatitis: a case report and literature review
- Long-term upadacitinib treatment in a patient with atopic dermatitis, bullous pemphigoid, and alopecia areata: a case report and review of the literature
- Tryptophan Metabolism in Pediatric Atopic Dermatitis: Shared Mechanisms, Age-Specific Biomarkers, and Emerging Therapies
- The Gut–Skin Axis in Pediatric Atopic Dermatitis: Nutritional Modulation, Microbiome Interactions, and Emerging Precision Approaches
BibTeX
@article{tsai2026phenotype,
title = {{Phenotype Switching in Pediatric Inflammatory Skin Diseases During Biologic Therapy: A Literature Review Focused on Atopic Dermatitis and Psoriasis}},
author = {Chu-Fei Tsai and Yu Yu},
journal = {International Journal of Molecular Sciences},
year = {2026},
month = sep,
doi = {10.3390/ijms27198740},
url = {https://www.mdpi.com/1422-0067/27/19/8740},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Phenotype Switching in Pediatric Inflammatory Skin Diseases During Biologic Therapy: A Literature Review Focused on Atopic Dermatitis and Psoriasis
AU - Chu-Fei Tsai
AU - Yu Yu
PY - 2026
DA - 2026/09/30
JO - International Journal of Molecular Sciences
DO - 10.3390/ijms27198740
UR - https://www.mdpi.com/1422-0067/27/19/8740
AB - Biologic therapies are highly efficacious for pediatric atopic dermatitis (AD) and psoriasis (PsO); however, their expanding use has led to increased reports of phenotype switching—a paradoxical condition where biologics induce new-onset immune-mediated dermatoses. To address clinical uncertainty regarding these complex reactions, this review evaluates real-world case reports, case series, and observational studies of pediatric AD and PsO patients who developed phenotypic switching during biologic therapy. Dupilumab is the most frequently implicated agent, commonly inducing psoriasiform, pustular, or palmoplantar eruptions in AD patients via a compensatory shift from Th2- to Th17-predominant immunity. Conversely, phenotype switching from IL-12/23 and TNF-α inhibitors remains rare in pediatric dermatology. For severe, refractory cases or AD-PsO overlaps, Janus kinase (JAK) inhibitors demonstrate significant rescue efficacy, provided appropriate baseline and ongoing laboratory monitoring is maintained. Pediatric patients experiencing biologic-induced phenotype switching can be successfully managed in clinical practice through early recognition and the implementation of the practical, evidence-based treatment algorithm proposed in this review.
SN - 1422-0067
ER -